WHITE PAPER

What Do Value Assessments Miss?

Rethinking Value Using New Health Economics Evidence

As drug prices continue to climb and novel therapies challenge traditional pricing models, there is increased momentum behind value-based care and value-based reimbursement.

In this rapidly-evolving climate, value assessments have become an essential component to the successful introduction of any new or innovative treatment. But what are they key drivers of this conversation?

Adapted from his popular webinar, Precision Xtract scientific advisor and Harvard professor Dr. Anupam Jena explores how the definition of value goes beyond quality and cost of care to include other important dimensions that should be factored into developing accurate value frameworks.

This new white paper will help you:

Understand drivers of value-based reimbursement

Address affordability issues

Redefine how value is measured for new technologies

To get your copy of this white paper, fill out the form below.

Contact us

Discover exactly what Precision can do for you. We look forward to learning about your needs, exploring how we can support you, and sharing our proven approaches. For information and inquiries, please contact:

Zac Stillerman

Zac Stillerman

President and General Manager

+1 240.316.3451

Larry Blandford, PharmD

Larry Blandford, PharmD

Executive Vice President and Managing Partner

+1 212.686.2650

J. Bruce Leavitt, MBA

J. Bruce Leavitt, MBA

Executive Vice President and Managing Partner

+1 203.487.5240

Ross Maclean, MD, PhD, MBA

Ross Maclean, MD, PhD, MBA

Executive Vice President, General Manager

+1 310.984.7708

Harry Grant Schiavi

Harry Grant Schiavi

Executive Vice President and Managing Partner

+1 302.379.1702